Results 81 to 90 of about 4,252 (213)

Yeast Surface Dual Display Platform for Rapid Discovery of Shark VNAR from a Semi-Synthetic Library Followed by Next-Generation Sequencing

open access: yesApplied Sciences, 2023
The shark-derived single-domain antibody VNAR (variable domain of new antigen receptor) has many advantageous features that make the VNAR suitable for improving current monoclonal antibody therapy deficiencies or disease diagnosis methods.
Chia-Hung Tsai   +3 more
doaj   +1 more source

Biopanning selection with combinatorial IgG/k library ID-A.

open access: yes, 2012
Library ID-A was selected by immunoaffinity on atherosclerotic plaque lysate. Results of screening ELISA assays of 30 clones after four rounds of biopanning selection is shown.
Maria Rosaria Piscopiello (145982)   +9 more
core   +1 more source

Nanobody‐Mediated c‐MYC Degradation Inhibits Tumor Cell Progression

open access: yesMedComm, Volume 7, Issue 4, April 2026.
A cell‐permeable nanobody strategy was developed to target the intrinsically disordered oncoprotein c‐MYC. A synthetic nanobody, M4, binds the central PEST region of c‐MYC (241–263) and promotes c‐MYC degradation by enhancing Thr58 phosphorylation. Conjugation of M4 to a cell‐penetrating peptide (CPP) generates CPM4, which efficiently accumulates in ...
Yuanyuan Xue   +7 more
wiley   +1 more source

SCREENING OF PEPTIDE RECEPTOR SEQUENCES FOR AMITROL DETECTION USING CHROMATOGRAPHIC BIOPANNING

open access: yes, 2018
Endocrine disrupting chemicals (EDCs) have been known as health threatening compounds and much attention has been paid in a research related with detection and/or removal from food sources and living environment.
Nguyen Thi Lien Thuong
core   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

open access: yesAdvanced Science, Volume 13, Issue 13, 3 March 2026.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao   +14 more
wiley   +1 more source

Identification of Novel Single Chain Fragment Variable Antibodies Against TNF-α Using Phage Display Technology [PDF]

open access: yesAdvanced Pharmaceutical Bulletin, 2015
Purpose: Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine, involved in both physiological and pathological pathways. Because of central role of TNF-α in pathogenesis of inflammatory diseases, in the current study, we aimed to identify ...
Ali Akbar Alizadeh   +2 more
doaj   +1 more source

An automated microfluidic biosensor with bispecific rabbit monoclonal antibody and nanozyme‐bioenzyme composite for dual antibiotic detection

open access: yesBMEMat, Volume 4, Issue 1, March 2026.
This study introduces an automated microfluidic biosensor for simultaneous detection of florfenicol and thiamphenicol in environmental water. By integrating a phage‐screened bispecific rabbit monoclonal antibody with a nanozyme‐bioenzyme composite, the system achieves sensitive dual‐antibiotic detection. Coupled with smartphone‐based sensing, it offers
Fuyuan Zhang   +11 more
wiley   +1 more source

Enrichment of positive phage clones by biopanning of Ph.D.-12 library.

open access: yes, 2015
Enrichment of positive phage clones by biopanning of Ph.D.-12 library.
Liquan Yu (762397)   +13 more
core   +1 more source

Improving Pharmacokinetics of Peptides Using Phage Display

open access: yesViruses
Phage display is a versatile method often used in the discovery of peptides that targets disease-related biomarkers. A major advantage of this technology is the ease and cost efficiency of affinity selection, also known as biopanning, to identify novel ...
Mallika Asar   +2 more
doaj   +1 more source

Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors

open access: yesPharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy